|
Trial Management Group |
Trial Activation |
Canadian Cancer Trials Group MEC.4 (Alliance A091201) - A Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide / Dacarbazine in Ocular Melanoma - was centrally activated on July 9, 2015.
The primary objective of the trial is to compare the progression-free survival rate at 4 months of patients with ocular melanoma treated with cabozantinib or temozolomide (or dacarbazine). Secondary objectives include to:
Any centres interested in participating on this trial should contact Dora Nomikos at 613-533-6430 or dnomikos@ctg.queensu.ca. |